Galway, Ireland, November 17, 2026
Medtronic plc has announced that the U.S. Food and Drug Administration (FDA) has cleared its Hugo™ Robotic-Assisted Surgery (RAS) system for use in general surgery procedures, expanding the technology’s clinical applications in the United States. The expanded 510(k) clearance marks an important milestone for Medtronic’s surgical robotics portfolio, allowing the system to be used across a broader range of abdominal surgical procedures beyond its existing urology applications in the U.S. The clearance covers all upper abdominal general surgical procedures, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection. It also includes lower abdominal procedures such as inguinal hernia repair and appendectomy. According to Medtronic, these approved procedures collectively account for approximately 3.5 million surgeries annually in the United States, representing more than half of all soft-tissue surgical procedures performed in the country each year. The regulatory decision strengthens Medtronic’s position in the growing robotic-assisted surgery market and provides hospitals and surgeons with additional technology options for performing complex surgical procedures.
FDA Clearance Expands Hugo RAS Across General Surgery
The newly granted FDA clearance significantly broadens the clinical applications of the Hugo robotic-assisted surgery system, enabling its use in multiple general surgery specialties. Previously, the system’s U.S. clinical applications focused on urological procedures. With the expanded authorization, surgeons can now use the platform for a wider range of upper and lower abdominal procedures, including gallbladder removal, bariatric surgery, hernia repair, intestinal resection and appendectomy. This expansion represents an opportunity for hospitals to integrate robotic-assisted technology into additional surgical departments and broaden access to minimally invasive surgical approaches. The clearance also builds on Medtronic’s longstanding experience in surgical technologies, including open and laparoscopic procedures. The company has worked with general surgeons for more than five decades and aims to extend this expertise into robotic-assisted surgical environments. According to Medtronic, the newly cleared applications position Hugo RAS to address a substantial portion of the U.S. general surgery market. The expansion also reflects the increasing adoption of robotic-assisted technologies across surgical specialties, where precision, flexibility and improved visualization are important considerations for surgical teams.
Modular Design and Advanced Surgical Instrumentation
A major feature of the Hugo RAS system is its modular robotic architecture, which allows surgical teams to configure and use only the robotic arms required for a particular procedure. The system provides flexibility in positioning the robotic arms according to the surgeon’s preferred technique and the patient’s anatomy. Its open surgeon console is designed to maintain communication and visibility between the surgeon, operating room team and patient, supporting collaboration during surgical procedures. In addition to its robotic platform, the system incorporates established Medtronic surgical instruments, including the LigaSure™ RAS Maryland instrument, which brings advanced vessel-sealing technology into robotic-assisted procedures. Medtronic reports that its LigaSure technology has been used in more than 45 million open and laparoscopic procedures, demonstrating its extensive clinical application in surgical environments. By combining robotic technology with established surgical instruments, the company aims to provide healthcare facilities with an integrated platform that supports different surgical requirements. The modular approach may also help hospitals adapt their robotic capabilities to varying procedure types and operating room needs.
Medtronic Strengthens Global Robotic Surgery Strategy
The FDA clearance comes as Medtronic continues expanding the global adoption of its Hugo robotic-assisted surgery platform. According to the company, Hugo RAS procedure volumes are growing at more than twice the rate of the overall robotic surgery market, with the system expected to surpass 50,000 procedures by the end of Medtronic’s fiscal year. General surgery has also emerged as the fastest-growing area for Hugo RAS procedures outside the United States, surpassing urology and gynecology. The expanded U.S. authorization is therefore expected to create additional opportunities for the company to strengthen its presence in general surgery and support wider hospital adoption. Medtronic’s Surgical business leadership highlighted that the expanded clearance provides U.S. hospitals with another robotic-assisted surgery option while helping address healthcare capacity and access challenges. Healthcare institutions are increasingly evaluating robotic platforms as part of their efforts to expand surgical capabilities and support advanced training programmes. The University of Illinois Health system also highlighted the potential of the technology to expand treatment options and strengthen surgical education. Overall, the FDA clearance of Hugo RAS for general surgery represents a significant development in medical robotics, expanding the range of procedures supported by the platform and reinforcing Medtronic’s commitment to advancing surgical innovation and improving access to robotic-assisted care.
Source: Medtronic press release



